DENVILLE, N.J., April 1, 2009 (GLOBE NEWSWIRE) -- Lantis Laser Inc. (Pink Sheets:LLSR) (http://www.lantislaser.com), announced today that it has filed a 15(c) 2-11 with FINRA to obtain a quotation on the OTC Bulletin Board. Stan Baron, President & CEO, pointed out that being a fully reporting company will provide the transparency and credibility that investors require in today's economic environment. Lantis filed an S-1 with the SEC which was deemed effective on February 17, 2009.
Lantis is developing a diagnostic imaging platform based on breakthrough, light-based technology that will provide the dentist with high resolution information, at up to 10 times x-ray, that is currently unobtainable. The company is building a combination diagnostic imaging platform that deploys the same light source and wavelength to enable optical coherence tomography (OCT) and Near Infrared transillumination (NIR) to be delivered for chairside scanning in a mobile cart. Lantis also intends selling the NIR as a standalone product as it provides significantly higher resolution than x-rays and without any ionizing radiation.
These two synergistic technologies provide for fast screening of teeth with NIR, and detailed structural information of decay and defects in tissue with OCT. This will give the dentist the ability to detect decay at a much earlier stage and arrest or reverse it with chemical rather than surgical means. Most importantly, OCT/NIR can provide detailed diagnostic information of the occlusal (biting surface) that is unobtainable with x-ray and where 80% of decay occurs. Dentistry is moving towards adopting Minimally Invasive Dentistry but currently lacks the imaging devices to detect the earliest stages of disease and defects.
The potential market for these products is large, with an estimated 200,000 dental offices in the U.S., Europe, Japan and other advanced countries practicing in an estimated 500,000 treatment rooms. Lantis has secured rights for these technologies based on its exclusive licensing and strategic component supply agreements.
Introduction of these diagnostic imaging modalities to the dental market is targeted for early 2010 after obtaining FDA clearance. OCT has been successfully commercialized in the field of ophthalmology by Zeiss Meditec who recently announced that it had sold 10,000 systems. OCT application in the cardiovascular field is expected to be the next major application to be commercialized. OCT is ideal for bio-medical imaging and research in many areas, including dermatology, cancer detection and optical biopsy.
About Lantis Laser
Lantis was formed to commercialize the application of novel technologies in the dental industry. The criteria for selected products include competitive edge, exclusivity and large market potential. Lantis has rights to the application of OCT technology in the field of dentistry under its license Agreements with Lawrence Livermore National Laboratory (exclusive) and LightLab Imaging (non-exclusive). Lantis also has exclusive rights to MEMS scanning technology from the University of Florida. The Company has an exclusive licence with The Regents of the University of California for the Near-infrared Imaging Technology (patent pending) and an exclusive development and supply Agreement with Axsun Technologies for its advanced OCT Engine. OCT was invented in the early 1990's at the Massachusetts Institute of Technology.
To find out more about Lantis Laser (Pink Sheets:LLSR), visit our website at www.lantislaser.com
Safe Harbor: Statements regarding financial matters in this press release other than historical facts are "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The company intends that such statements about the Company's future expectations, including future revenues and earnings, technology efficacy and all other forward-looking statements be subject to the safe harbors created thereby. The Company is a development stage company who continues to be dependent upon outside capital to sustain its existence. Since these statements (future operational results and sales) involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results.